Streetbeat News

Stock Prices

GASS

StealthGas (NASDAQ:GASS) reported Q3 earnings with an EPS of $0.16, beating estimates by 6.67% but with a revenue decrease of $231 thousand from the same period last year. Despite beating EPS estimates in the past quarters, the share price experienced a minor drop the following day last quarter.

Portfolio Pulse from Benzinga Insights

November 21, 2023 | 2:20 pm

SEED

Origin Agritech Ltd. (NASDAQ:SEED) provided a business update for FY23, expecting revenue of $12M-$13M, a 60%-70% increase from FY22. Net income is projected at $16M-$17M, including a one-time $19M gain from a building sale. Operating profit is anticipated to be around $2M. The company highlighted advancements in agricultural biotechnology, including a triple-stack trait corn and a novel gene editing method. They also discussed the potential approval of GMO corn hybrids in 2024, advancements in nitrogen-efficient corn, and expansion plans for nutrition-enhanced corn (NEC). The company is in discussions with Muyuan Foods for potential collaborations and expects to expand NEC corn planting. Origin Agritech's CEO expressed confidence in the company's future and dissatisfaction with the current stock price, indicating it undervalues the company's potential.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 2:19 pm

GASS

StealthGas (NASDAQ:GASS) reported Q3 2023 earnings of $0.16 per share, surpassing the consensus estimate of $0.15. Sales reached $34.65M, exceeding the $27.50M estimate but marking a slight decrease from the previous year's $34.89M.

Portfolio Pulse from saritha@benzinga.com

November 21, 2023 | 2:16 pm

HIBB

Hibbett, Inc. (NASDAQ:HIBB) shares surged after reporting Q3 sales of $431.92 million, surpassing analyst expectations of $416.02 million. Despite a slight 0.3% Y/Y net sales decrease, the company's Q3 EPS of $2.05 exceeded estimates of $1.17. E-commerce sales grew by 12.6% Y/Y, while brick-and-mortar sales fell by 5.4%. Gross margin slightly declined due to higher promotional activity. Hibbett opened ten new stores, updated its FY24 EPS outlook to $8.00-$8.30 from $7.00-$7.75, and expects total sales to be flat to up ~2.0% for FY24. The stock price rose by 16.56% to $62.50 in premarket trading.

Portfolio Pulse from Nabaparna Bhattacharya

November 21, 2023 | 2:16 pm

GASS

StealthGas (NASDAQ:GASS) reported Q3 earnings of $0.31 per share, surpassing the $0.15 estimate by 106.67%, and a 93.75% increase from last year's $0.16. Sales reached $34.65M, exceeding the $27.50M estimate by 26.01%, despite a slight 0.66% decrease from last year's $34.89M.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 2:13 pm

AAPL

AI

AMD

AMZN

CPA

DIS

MSFT

NVDA

QQQ

TSLA

The top 10 trending stocks on WallStreetBets as of November 21, 2023, are NVDA, AI, MSFT, QQQ, TSLA, AMZN, AAPL, CPA, AMD, and DIS, according to data from Swaggy Stocks.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 2:12 pm

XPOF

Xponential Fitness, Inc. (XPOF) has reached a significant milestone by opening its 3,000th studio, CycleBar Loveland, in Colorado. CEO Anthony Geisler thanked franchisees and employees for their contributions to this achievement. Xponential Fitness has a presence in 23 countries and plans for continued growth. The owners of CycleBar Loveland, Sydnie and Zack Whitmer, expressed gratitude for Xponential's support and commitment to providing exceptional fitness experiences.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 2:10 pm

SNDX

Syndax Pharmaceuticals announced that data from its pivotal AUGMENT-101 trial of Revumenib for treating relapsed/refractory KMT2Ar acute leukemia has been selected for a late-breaking presentation at the 65th ASH Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 2:09 pm

SCLX

Scilex Holding Company (NASDAQ:SCLX) announced an increase in manufacturing of ELYXYB, a non-opioid pain management product for migraines, to meet rising demand. The company has produced its first commercial batch with Scilex labeled ELYXYB, aiming to address the needs of future customers. ELYXYB is FDA-approved and has shown effectiveness in clinical trials. The U.S. migraine drug market is estimated at $4.1 billion in 2022. Scilex's CEO expressed excitement about ELYXYB's potential since its April 2023 launch.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 2:09 pm

SGN

Signing Day Sports, Inc. (SGN) is focusing on growth and partnerships, leveraging its app for high school athlete recruitment. The app supports multiple sports and aims to adapt to more, funded by its IPO proceeds. The company plans to use digital marketing to raise student-athlete awareness and increase user revenue. Amidst a stock price decline since trading on the NYSE American exchange, SGN suspects illegal short selling and has initiated an investigation. The company maintains strong support from legacy stockholders and is committed to advancing student-athlete education and opportunities.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 2:08 pm